RAD Virtual Symposium 2020 - On Demand

Although diagnosis of atopic dermatitis is straightforward in children, its diagnosis is challenging in adults. Advances in research on AD epidemiology, burden and comorbidities have transformed the understanding of the course of AD, including risk factors, age of onset, disease severity and persistence, and health outcomes. Clinicians may not be aware of the epidemiology of AD for proper risk stratification, patient education and therapeutic decision-making. Atopic dermatitis is a heterogeneous disorder with variable severity of signs and symptoms, and impact on quality of life. Clinicians may not be able to assess AD severity accurately in order to optimize therapy.

Our virtual meeting allows clinicians to understand this disease better through the latest in research, world-renowned faculty speakers, case presentations and Q&A sessions.

  • Archive - Revolutionizing Atopic Dermatitis – Virtual Conference
  • Release date: May 5, 2020
  • Expiration date: May 4, 2021
  • Estimated time to complete activity: 6 hours
  • Jointly provided by Postgraduate Institute for Medicine and Foundation for Dermatology Education
  • This activity is supported by an independent educational grant from Incyte

Target Audience

This activity is intended for physicians and other healthcare providers engaged in the care of patients with atopic dermatitis.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Diagnose and assess the severity of atopic dermatitis
  • Identify the heterogeneous clinical characteristics and different phenotypes of atopic dermatitis
  • Recognize the high patient burden of atopic dermatitis
  • Use improved understanding of pathophysiology, disease course, and treatments in therapeutic decision-making for atopic dermatitis and related comorbidities
  • Use evidence-based treatment approaches for atopic dermatitis

Faculty

Marissa Ayasse
Research Fellow
The George Washington University of Medicine and Health Sciences
Department of Dermatology
Washington, DC, USA

No COIs to report.

Andrew Blauvelt, MD, MBA
Oregon Health & Science University
Portland, Oregon

Investigator: AbbVie, Aclaris, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, FLX Bio, Forte, Galderma, Janssen, Leo, Novartis, Ortho, Pfizer, Regeneron, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB Pharma, and as a paid speaker for AbbVie.

Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health and University of Colorado, School of Medicine
Denver, Colorado

Consulting fees: Eli Lilly, Regeneron, Sanofi-Genzyme.
Fees for non-CME/CE services received directly from a commercial interest: Regeneron and Sanofi-Genzyme.
Contracted research fees: Regeneron and Incyte.

Korey Capozza, MPH
Founder/Director
Global Parents for Eczema Research
Los Angeles, California

Consulting Fees: Sanofi Regeneron, Leo Pharma

Melinda Gooderham, MSc, MD, FRCPC
Dermatologist, SKiN Centre for Dermatology
Assistant Professor, Queen’s University
Clinical Investigator, Probity Medical Research
Peterborough, ON, Canada

Contracted Research: Abbvie, Amgen, Arcutis, Boehringer Ingelheim, BMS, Celgene, Dermira, Eli Lilly, Galderma, Janssen, LEO Pharma, Merck, Novartis, Regeneron, UCB, SUN, Bausch
Other: Received, personal fees, honoraria, and/or nonfinancial support from Pfizer Inc., AbbVie, Akros, Amgen, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermira, Eli Lilly, Galderma, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Novartis, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, UCB, and Valeant/Bausch.

Amy Paller, MS, MD
Walter J. Hamlin Chair and Professor of Dermatology
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

No COIs to report.

Kim Papp, MD, PhD
Founder and President
Probity Medical Research Inc.
Waterloo, ON, Canada

No COIs to report.

Jonathan I. Silverberg, MD, PhD, MPH
Conference Chair, Revolutionizing Atopic Dermatitis
Professor of Dermatology
Director of Clinical Research
Director of Patch Testing
The George Washington University School of Medicine and Health Sciences
Washington, DC

Consulting fees: Abbvie, AnaptysBio, Arena, Asana, Boehringer-Ingelheim, Celgene, Dermavant, Dermiera, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa, Leo, Menlo, Novartis, Pfizer, Regeneron, Sanofi-Genzyme.
Fees for non-CME/CE services received directly from a commercial interest: Regeneron and Sanofi-Genzyme.
Contracted research fees received from Galderma and GlaxoSmithKline.

Eric Simpson, MD, MCR
Professor of Dermatology, School of Medicine
Oregon Health & Science University
Portland, Oregon

Consulting fees: AbbVie, Eli Lilly Co., Galderma, Kyowa Hakko Kirin, Leo Pharmaceutical Co., Merck, Pfizer, Regeneron Pharmaceuticals, Inc., and a consultant with honorarium for AbbVie Inc., Eli Lilly Co., Forte Bio, Galderma, Leo Pharmaceutical Co., Menlo Therapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals. Inc., Sanofi Genzvme. and Valeant.
Contracted Research: AbbVie, Eli Lilly Co., Galderma, Kyowa Hakko Kirin, Leo Pharmaceutical Co., Merck, Pfizer, Regeneron Pharmaceuticals, Inc., and a consultant with honorarium for AbbVie Inc., Eli Lilly Co., Forte Bio, Galderma, Leo Pharmaceutical Co., Menlo Therapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals. Inc., Sanofi Genzvme. and Valeant.

Ms. Smith Begolka, MBS
National Eczema Association (NEA)
Vice President, Scientific & Clinical Affairs
Novato, California

Consulting fees: AbbVie, Eli Lilly, Forte Bio, Galderma, Incyte, LEO Pharma, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, and Valeant. Investigator fees received from AbbVie, Eli Lilly, Galderma, Kyowa Hakko Kirin, LEO Pharma, Merck, Pfizer, and Regeneron.

Planners and Managers

The PIM planners and managers have nothing to disclose. The Foundation for Dermatology Education planners and managers have nothing to disclose.

Joint Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Foundation for Dermatology Education.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Media

Internet

Computer System Requirements

WINDOWS

  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome

MAC OS

  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.11, 10.12, and 10.13
  • Mozilla Firefox, Apple Safari, Google Chrome

MOBILE

  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Please click register below to create a new account and register for the on demand program.